Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.51 |
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | HTR2B | P41595 | 2/20 | 0.51 |
| ▸ | CCR5 | P51681 | 1/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4463836 | 1.00 | OPRM1 (0.57) | OPRM1SIGMAR1CHRM2CHRM3KCNH2 | |
| SCHEMBL3817982 | 0.83 | OPRM1 (0.59) | OPRM1SIGMAR1CHRM2CHRM3KCNH2 | |
| SCHEMBL1220330 | 0.83 | OPRM1 (0.59) | OPRM1SIGMAR1CHRM2CHRM3KCNH2 | |
| Hydrochloric Acid SCHEMBL4469376 | 0.82 | OPRM1 (0.57) | OPRM1SIGMAR1CHRM2CHRM3KCNH2 | |
| SCHEMBL10654998 | 0.82 | LTA4H (0.64) | OPRM1SIGMAR1CHRM2CHRM3KCNH2 | |
| Hydrochloric Acid SCHEMBL4469375 | 0.82 | OPRM1 (0.57) | OPRM1SIGMAR1CHRM2CHRM3KCNH2 | |
| SCHEMBL4464056 | 0.81 | OPRM1 (0.57) | OPRM1SIGMAR1CHRM2CHRM3KCNH2 | |
| SCHEMBL5718487 | 0.81 | OPRM1 (0.57) | OPRM1SIGMAR1CHRM2CHRM3KCNH2 | |
| SCHEMBL13920772 | 0.81 | CCR5 (0.61) | KCNH2CCR5 | |
| SCHEMBL3075042 | 0.80 | CHRM2 (0.63) | SIGMAR1CHRM2CHRM3DRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507760-B2 | N-type calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-03-24 | — | — | US | disclosed |
| EP-1718633-A1 | N-TYPE CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005070919-A1 | N-TYPE CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2005-08-04 | — | — | WO | disclosed |
| US-20050165065-A1 | N-type calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165065-A1 | N-type calcium channel blockers | CACNA1B, CACNA1C, CACNA1D | OPRM1 592/4885SIGMAR1 2850/4885CHRM2 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.